Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease
Chandler A. Long(Duke Medical Center), Mark R. Nehler(Bühler (United Kingdom)), Manesh R. Patel(Clinical Research Institute), Lars Norgren(Örebro University), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Juuso Blomster(AstraZeneca (Netherlands)), F. Gerry R. Fowkes(Duke University Hospital), William R. Hiatt(University of Colorado Anschutz Medical Campus), Iris Baumgärtner(University of Bern), Frank W. Rockhold(Amyloidosis Foundation), Jeffrey S. Berger(New York University), W. Schuyler Jones(Duke University), Brian G. Katona(AstraZeneca (United States)), Hillary Mulder(Clinical Research Institute)
Cited by 43
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k